STX18: A Potential Drug Target and Biomarker (G53407)

Target Name: STX18

NCBI ID: G53407

STX18

STX18: A Potential Drug Target and Biomarker

Stuximabin (STX18) is a drug used to treat relapsed or refractory diffuse large B-cell lymphoma (DLBL), a type of blood cancer that affects the bone marrow and other parts of the body. It is a small molecule inhibitor of the B-cell maturation antigen (BCMA) receptor, which is a protein that encourages the growth and survival of cancer cells. By blocking this receptor, STX18 works as a targeted therapy to treat cancer cells that produce high levels of BCMA.

The Importance of BCMA as a Cancer Receptor

BCMA is a transmembrane protein that is expressed in most tissues and cell types in the body. It is a key regulator of the immune response and has been implicated in the development and progression of many types of cancer. In particular, it has been shown to be highly expressed in multiple myeloma, a type of blood cancer that is characterized by the production of large amounts of BCMA by the cancer cells.

The identification of BCMA as a cancer receptor has significant implications for the treatment of cancer. Because BCMA is expressed in most tissues and cell types, it is a promising target for drugs that can inhibit its activity. This is because such drugs have the potential to treat a wide range of cancer types, rather than being limited to specific types of cancer.

The Discovery of STX18

STX18 is a small molecule inhibitor of BCMA, which was identified through a screening process for drugs that could inhibit BCMA activity. The compound was shown to be effective in preclinical studies against multiple myeloma cells and primary human myeloma samples.

The Benefits of STX18 as a Drug Target

STX18 has several potential benefits as a drug target for cancer. First, it targets a protein that is expressed in most tissues and cell types, which makes it a broad and effective treatment for a wide range of cancer types. Second, it is a small molecule inhibitor, which means it has a relatively low risk of toxic side effects. Finally, because it is a targeted therapy, STX18 is able to selectively target cancer cells that produce high levels of BCMA, which can lead to a more effective treatment of cancer.

The Potential for Expanded Use of STX18

The identification of STX18 as a potential drug target has significant implications for the treatment of multiple myeloma and other types of cancer. Because it is a small molecule inhibitor of BCMA, STX18 has the potential to be used as a targeted therapy for a wide range of cancer types.

In addition to its potential use as a treatment for cancer, STX18 also has the potential to be used as a biomarker for monitoring the effectiveness of cancer treatments. By measuring the levels of BCMA in cancer cells before and after treatment, researchers can determine the effectiveness of STX18 and other therapies. This could be a valuable tool for monitoring the progress of cancer treatments and identifying new approaches for cancer treatment.

Conclusion

STX18 is a small molecule inhibitor of the B-cell maturation antigen (BCMA) receptor, which is expressed in most tissues and cell types in the body. It has been shown to be effective in preclinical studies against multiple myeloma cells and primary human myeloma samples. As a potential drug target and biomarker, STX18 has the potential to be used as a targeted therapy for a wide range of cancer types. Further research is needed to determine its safety and effectiveness as a treatment for cancer.

Protein Name: Syntaxin 18

Functions: Syntaxin that may be involved in targeting and fusion of Golgi-derived retrograde transport vesicles with the ER

The "STX18 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about STX18 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets